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SIVrcms the red-capped mangabey (Cercocebus torquatus torquatus). Although this virus
infects macaques and human PBMCs, its pathogenic potential is unknown. We serially passaged SIVrcm
through 9 rhesus macaques to assess its potential for virulence. SIVrcm infected all macaques with peak
viremia 2 weeks postinfection yet viral loads decreased to undetectable levels about one month after
inoculation. Remarkably, SIVrcm replication and virulence did not increase following 7 serial passages. While
CD4+ T cells in the gut were decreased in early infection, proportions of memory CD4+CCR5+ T cells were not
affected. Three SIVrcm-infected macaques were subsequently challenged with SIVmac251 to assess the
potential for superinfection. Interestingly, animals previously infected with SIVrcm had 100 fold lower levels
of SIVmac251 in plasma compared to naive animals inoculated with SIVmac251. These results suggest that
SIVrcm is nonpathogenic and may be useful for examining effective immune responses in SIV infection.
© 2008 Elsevier Inc. All rights reserved.IntroductionSimian immunodeﬁciency virus (SIVrcm) was discovered in red-
capped mangabeys (RCM) (Cercocebus torquatus torquatus) in Gabon
and Nigeria, Africa (Beer et al., 2001; Chen et al., 1998; Georges-
Courbot et al., 1998; Smith et al., 1998). Thus far, SIVrcm has only been
partially characterized and has not been classiﬁed into any of the 6
major lineages of SIV by full-length genome phylogenetic analysis.
SIVrcm has some speciﬁc characteristics distinguishing it from other
SIVs. First, the genome of the virus, has a vpx gene similar to HIV-2/
SIVsm/SIVmac, whereas its pol region is genetically close to SIVcpz
and gave rise to the theory that SIVcpz is a recombinant of SIVrcm and
SIVgsn (a virus from greater spot-nosed monkey) (Bailes et al., 2003).
SIVrcm or a close relative may be involved in SIVcpz evolution.
Secondly, SIVrcm is the only known primate lentivirus that uses
CCR2b as its major co-receptor for entry, rather than CCR5 or CXCR4
(Chen et al., 1998; Zhang et al., 2000).ology, Tulane National Primate
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l rights reserved.The reasons that SIVrcm uses CCR2b as a coreceptor are not well
understood. However, it has been hypothesized that this is an
evolutionary adaptation in response to a high frequency of a 24 base
pair (bp) deletion analogous to the delta 32mutation in humans in the
CCR5 gene. This results in lack of expression of CCR5 on cells,
rendering them uninfectable by viruses that rely on CCR5 for entry
(Chen et al., 1998). With rare exceptions, SIVs do not cause AIDS in
their natural hosts (Ling et al., 2004; Pandrea et al., 2001). However,
cross-species transmission of SIV from a natural host (mangabey) to a
naive host (macaque) resulted in the SIV-macaque model of AIDS
primarily used today to examine the pathogenesis of HIV infection.
Similarly, SIVrcm appears to be minimally pathogenic in its natural
host, although studies are limited in this species (Georges-Courbot
et al., 1998). SIVrcm experimentally infects other species such as
cynomologus (Macaca fascicularis) and Indian-origin rhesus macaques
(Macaca mulatta) (Georges-Courbot et al., 1998; Smith et al., 1998).
However, whether serially passage SIVrcm has the potential to
increase pathogenicity or cause an AIDS-like disease in Ind Rh
macaques is unknown. We hypothesized that serial passage of this
virus in a species that was naive to this virus would increase its
potential for pathogenicity. The goal of this study was to determine
whether serial passage of SIVrcm through rhesus macaques of Indian
origin would increase its potential for pathogenicity. Serial passage of
Fig. 1. Sequential plasma viral loads of SIVrcm from each serial passage in Indian rhesus
macaques. A total of 7 passages were performed. Passage 1 to 6 had one animal per
passage. Passage 7 had three animals — CG29-p7, CF56-p7 and G454-p7. The passage
number is designated as p1, p2, p3 etc.
Fig. 2.Dynamics of CD4+ and CD8+ Tcells in blood after SIVrcm serial passages in Indian
rhesus macaques. CD3+ T cell gated lymphocytes were analyzed for the expression of
CD4 and CD8. The connected line represents the mean number of cells from the 9
SIVrcm-infected monkeys (a and b).
Fig. 3. The percentages of intestinal CD4+ T cells (a) and intestinal memory CD4+CCR5+
T cells (b) during SIVrcm infection. Data are presented as scatter dot plots. ⁎Indicates
signiﬁcance of pb0.002 between day 0 and day 28; ⁎⁎: pb0.012 compared between
day 0 and day 90.
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humans (Drucker et al., 2001). Since SIVrcm can replicate in rhesus
and human lymphocytes, such studies could help us better under-
stand the potential for cross species transmission of viruses.
Another goal was to determine if SIVrcm has a beneﬁcial impact by
preventing or alleviating “superinfection” by pathogenic strains of
SIVmac. CCR5 is the primary coreceptor used by HIV and SIVmac. In
fact, a number of CCR5 fusion inhibitors are now available or in
development as therapies for HIV. It is also known that CXCR4
utilizing strains may emerge in HIV-infected patients in late infection,
which sometimes are associated with increased viral loads and amore
severe disease progression (Mild et al., 2007). However, it is still
debated as to whether the pressure of CCR5 inhibitors or co-infection
with other viral strains with different chemokine receptor usage may
pressure a change in chemokine receptor usage of HIV. CCR2 and CCR5
share some sequence similarity, are located on the same chromosome,
and HIV has the potential to use CCR2 as coreceptor (Frade et al., 1997).
Therefore, blocking CCR2 expression by SIVrcm infection could affect
the course or chemokine receptor expression of HIV infection. Thus,
macaques previously infected with SIVrcm were subsequently
challenged with pathogenic SIVmac251 and viral replication and
pathogenicity were compared between dual infected and SIVmac251-
only infected macaques.
In this study, 9 Ind Rh macaques were used for serial passage of
SIVrcm. Three were superinfected with SIVmac251 after chronic
SIVrcm infection. We found that the capacity of SIVrcm for replication
in Ind Rh remained attenuated after serial passage. Although partial
CD4+ T cell depletion occurred in the gut, mucosal memory
CD4+CCR5+ T cells were not signiﬁcantly reduced during SIVrcm
infection. Serial passage of SIVrcm in Ind Rh did not signiﬁcantly
increase its virulence and no signs of AIDS were observed. We propose
that SIVrcm infection mainly infects the monocyte/macrophage
lineage on which CCR2 is expressed at high levels, and that memory
CD4+ T Cells, the major target for HIV/SIVmac, are spared in SIVrcm
infection. Furthermore, prior infection with SIVrcm resulted in
signiﬁcantly decreased viral loads and decreased the pathogenicity
of SIVmac251 in “superinfected” animals.
Results
Viral replication of SIVrcm in Indian rhesus macaques by serial passage
A total of seven passages of SIVrcm were performed. All monkeys
had a transient peak viremia from 104 to 106 copies/ml at day 11–14
after SIVrcm infection, which decreased rapidly to undetectable levels
in all except the 5th passage animal, R265-p5, which had 103 copies in
Fig. 4. In vitro replication of SIVrcm isolated from 4 serially infected animals. The
replication was monitored by SIV Gag p27 antigen measurement in culture super-
natants by ELISA.
Fig. 5. CCR2 and CCR5 expression on different T cell subsets. Animal M854 was tested
before SIVrcm infection (M854-p6-1), day 14 of infection (M854-p6-2) and at the time
of necropsy (M854-p6-3). Animal R265 was tested at day 14 of infection.
40 B. Ling et al. / Virology 379 (2008) 38–44the 2nd month of infection (Fig. 1). Notably, the median levels of
SIVrcm loads were relatively low compared to SIVmac infection of Ind
Rh. Although most animals remained healthy, one animal (M854-p6)
was euthanized due to severe pneumonia. However, plasma viral
loads in this animal did not increase signiﬁcantly over those of other
animals in previous passages. Thus, to examine whether the
development of disease was associated with a more pathogenic
SIVrcm infection, a 7th passage of SIVrcm was performed in 3 Ind Rh
(CF56-p7, CG29-p7 and G454-p7), which received plasma derived
from monkey M854-p6 at the time of peak viremia. All 3 monkeys
were infected with SIVrcm, but viral loads in plasma were not
signiﬁcantly increased, and no clinical signs or disease was noted in
these animals. In summary, there was no signiﬁcant increase in virus
replication or virulence after 7 passages of the SIVrcm in Ind Rh.
Dynamics of T cell subsets in the peripheral blood and gut
Dynamics of CD4+, CD8+ T cells were monitored in the peripheral
blood and gut throughout SIVrcm infection. There was no signiﬁcant
difference in peripheral blood between animals in different passages
as shown in Fig. 2 panels a and b. Moreover, there were no signiﬁcant
changes in CD4+ T cell counts after SIVrcm infection compared with
baseline CD4+ T cell counts before infection, although a transient
decrease of CD4+ cells was seen at day 14 along with a slight increase
in the CD8+ cells. However, no relationship between serial passage and
changes in CD4+ T cells was detected.
Interestingly, the percentage of CD4+ T cells in the gut showed a
signiﬁcant decrease at day 28 (pb0.002) and day 90 (pb0.012), but not
at day 14 (p=0.105). (Fig. 3a). However, there was no correlation
between the time of serial passage and the degree of intestinal CD4
depletion between animals. Interestingly, the proportions of intestinal
memory (CD45RA negative) CD4+CCR5+ T cells, the main targets of
SIVmac and HIV (Brenchley et al., 2004; Mehandru et al., 2004; Veazey
et al., 1998) remained relatively stable in the gut throughout infection
(Fig. 3b), which is likely due to the fact that this virus does not use
CCR5 as a coreceptor for infection and entry (Chen et al., 1998; Zhang
et al., 2000).
SIVrcm replication in vitro
To test the capability of viral replication in vitro after serial
passaging in animals, viruses were isolated from 4 animals AT74-1,
AT83-p2, AT87-p3 and L836-p4. Viruses from AT74-p1 and L836-p4
had very similar low viral replications, virus from AT83-p2 started to
grow slowly and had higher replication than AT74-1 and L836-p4 atday 21 of culture. Notably, AT87-p3 had a signiﬁcantly higher level of
viral replication and peaked at day 17 of culture (Fig. 4). This result was
not consistent with the observation in vivo shown in Fig. 1, indicating
in vitro replication does not reﬂect the ability of replication in vivo, in
agreement with the observations in a report (Gautam et al., 2007). In
addition, the SIVrcm was also able to replicate in human PBMCs as
well as in human T cell line Molt4clone8 (data not shown).
Expression of SIVrcm coreceptor CCR2 on monocytes
To determine if CCR2 expression changed after SIVrcm infection,
we tested the level of CCR2 on CD20+ B cells, CD4+ T cells and CD14+
monocytes of M854-p6 at multiple time points during SIVrcm
infection and one time point in animal R265-p5. As shown in Fig. 5
panel a, CD4+ T lymphocytes and B lymphocytes had little or no
expression of CCR2, but monocytes had high expression of CCR2.
However, no changes in the expression of CCR2 were observed on
monocytes after SIVrcm infection. Moreover, monocyte counts in
blood were not signiﬁcantly different throughout SIVrcm infection,
although a minor increase was noted from day 7 through day 28, with
highest levels observed at day 17 P.I. (Fig. 5b).
SIVmac251 superinfection in SIVrcm infected animals
Since SIVrcm replication in infected animals decreased rapidly in
most animals to undetectable levels (b102 copies/ml), we wanted to
determine if prior infection a suppressive or enhancing effect after co-
infection with a more pathogenic SIV. Thus, we challenged 3 Ind Rh
that had been used in three different passages (AT87-p3, L836-p4 and
R265-p5) with SIVmac251, one year after SIVrcm infection when
SIVrcm viral loads were still undetectable. A cohort of 8 Indian rhesus
macaques on an unrelated study that received the same dose of
SIVmac251 intravenously were used for viral load comparison. In
Fig. 6. Comparison of median viral loads of SIVmac251 in plasma of two groups of
animals. Solid line shows animals that were infected with SIVrcm prior to SIVmac251
challenge. The dashed line indicates animals that were infected with SIVmac251 alone.
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100 fold lower than those in SIVmac251 infection alone at both the
peak of viremia as well as in the chronic stage of infection and viral set
point (Fig. 6). This suggested that the prior SIVrcm infection resulted
in some level of protective immunity against challenge with the more
pathogenic SIVmac251.
Clinical outcome of SIVrcm after serial passage or superinfection
with SIVmac251
Seven of 9 SIVrcm-infected animals remained alive and had no
signs of diseases throughout this study. One monkey (M854-p6)
developed severe bacterial pneumonia and was humanely eutha-
nized at day 42 after SIVrcm infection. Corynebacterium was isolated
from the lungs. However, in the absence of low CD4 counts,
recognized opportunistic infection, or giant cells in the lungs, the
pneumonia could not be attributed to SIV infection or immunosup-
pression. Furthermore, we do not believe the pneumonia was related
because the 3 macaques (CF56-p7, CG29-p7 and G454-p7) that
received plasma from M854-p6 at peak viremia did not develop
disease. Monkey L836-p4, which was in the 4th passage and
subsequently challenged with SIVmac251, was euthanized due to
non-AIDS disease with low SIVmac251 load of 3165 copies/ml.
Animal R265-p5 was euthanized due to neoplasm/lymphoma with
viral load at 105 copies/ml at 24 months after SIVmac251 infection.
Animal AT87-p3 is still healthy after 35 months of SIVmac251
infection with the viral loads stable at 103 copies/ml.
Discussion
Experimental infection of SIVrcm in Ind Rh has been previously
reported (Smith et al., 1998). However, only 2 animals were studied
and the methods for quantifying viral replication were relatively
insensitive compared to current quantitative RT-PCR techniques.
In this study, we describe the following ﬁndings: a) serial passage
of SIVrcm did not signiﬁcantly increase its virulence for Ind Rh; b)
SIVrcm replication was signiﬁcantly lower than SIVmac infection
alone in Ind Rh; c) intestinal mucosal CD4+ T cells decreased
signiﬁcantly after one month of infection, but intestinal memory
CD4+CCR5+ T cells were not signiﬁcantly impacted; and d) Macaques
superinfected with SIVmac251 following SIVrcm infection had lower
levels of viral replication and a better prognosis than animals
challenged with SIVmac alone.Our study of 7 serial passage in Ind Rh showed that although
SIVrcm successfully infected this species, but viral virulence did not
increase with passage. Serial passage of SIVs in one species or passage
of virus in species other than its natural hosts may result in increasing
virulence (Dewhurst et al., 1990; Fultz et al., 1989; Novembre et al.,
1993; Tan et al., 1999). In contrast, serial passage may not increase
viral virulence and not result in AIDS-like diseases in SHIV162p3 and
p4 infected rhesus macaques (Teleshova et al., 2006a; Teleshova et al.,
2006b). Moreover, serial passage of a virus could generate attenuated
virus which may eventually be exploited for vaccine design or testing,
such as in the development of the early rabies vaccines ﬁrst developed
by Pasteur over a century ago.
With regard to hosts, it appears that pig-tailed macaques (Macaca
nemestrina) are more susceptible to disease from SIVs such as SIVagm
(Hirsch et al., 1995), SIVsun, SIVlhoest (Beer et al., 2005) and HIV-2
(Otten et al., 2000; Pullium et al., 2001). However, the above viruses
have not been reported to be pathogenic for Ind Rh. The low
pathogenicity of SIVrcm for Ind Rh may due to its unique usage of
CCR2 as co-receptor.
It is noteworthy that although SIVrcm infectionwas not pathogenic
in monkeys, a signiﬁcant loss of gut CD4+ T cells occurred, and to a
lesser extent in blood. These results suggest that some level of
intestinal CD4+ T cell loss is common to all SIV infections, whether or
not the infection is the result of an ultimately pathogenic SIVmac or
nonpathogenic SIVsm, SIVagm or SIVrcm infection (Gordon et al.,
2007; Ling et al., 2002, 2007; Pandrea et al., 2007; Veazey et al., 1998,
2000). Interestingly, however, the proportions of memory CD4+CCR5+
T cells in the gut of these animals did not show signiﬁcant losses after
SIVrcm infection, whereas memory CD4+CCR5+T cells are depleted in
the gut of SIV-infected macaques, mangabeys, and AGMs after various
SIV infections and in HIV-infected humans (Brenchley et al., 2004;
Gordon et al., 2007; Mattapallil et al., 2005; Mehandru et al., 2004
2354; Pandrea et al., 2007; Veazey et al., 1998; Veazey et al., 2000).
This observation likely due to the unique co-receptor usage of this
virus, as it utilizes CCR2 and not CCR5 for entry into cells. As a
consequence of its unique CCR2 tropism, SIVrcm infection may use
different replication strategies from other SIVs. This virus may target
the monocyte–macrophage lineage rather than lymphocytes, since
CCR2 is expressed mainly on monocytes. Development of a SIVrcm
infectionmodel in rhesusmacaque could be useful in studying the role
of macrophages in the establishment and control of infection.
Monocytes and macrophages are considered to be crucial reservoirs
of HIV-1 infection (Aquaro et al., 2006; Brown et al., 2006; Crowe et al.,
2003; Zhu, 2002; Zhu et al., 2004), and serve as an important strategy
for HIV-1 to evade and resist immune pressure (Stevenson, 2003).
Furthermore, macrophages are less susceptible to viral cytopathic
effects (Stevenson, 2003) which may explain why we did not detect
signiﬁcant changes in monocytes in this study. Understanding SIVrcm
tropism and viral entry may help to determine the relationship
between tropism and infectivity and provide insights into the
development of rational therapeutic antiviral strategies in HIV
infection.
SIVrcm interference of SIVmac251 infection may be via interac-
tion or competition between CCR5 and CCR2. CCR2 has a strong
linkage with CCR5 as they are located in the same region of human
genome and in the same orientation (Samson et al., 1996). A recent
study demonstrated that ongoing parallel gene conversion between
CCR2 and CCR5 occurred and might be a potential mechanism for
receptor dimerization (Vazquez-Salat et al., 2007). Another study
has demonstrated that CCR2 has an amino-terminal domain that can
bind to HIV-1, indicating a potential role of coreceptor for HIV-1
infection (Frade et al., 1997), thus there are reasons to presume that
coreceptor usage switch could occur under the pressure of CCR5
inhibitor therapy in HIV-1 infection. It is also reported that MCP-1
binding to CCR2b efﬁciently prevents CCL4 (MIP-1β) and CCL5
(RANTES) binding to CCR5 on cells expressing both CCR2 and CCR5
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inhibited by MCP-1 (Alkhatib et al., 1997). SIVrcm binding to CCR2
may prevent MCP-1/CCR2 binding and lead to a higher afﬁnity of
CCR5 binding to its ligands, which might provide fewer opportunities
for CCR5/SIVmac251 binding, which could reduce SIVmac251 entry.
Although we have not yet shown the molecular mechanisms that
underlie SIVrcm-associated reduction of SIVmac251 replication, our
data may bear on vaccine development by showing that prior SIVrcm
infection affects replication of a distantly related virus in vivo.
Another possibility is that immune responses may have protective
effects. Some studies have demonstrated that prior SHIV or SIV
infection control super-challenged virulent SIV or SHIV infection
(Genesca et al., 2007; Tsukamoto et al., 2007) and Veazey—
unpublished observation). The mechanisms may be due to enhanced
CD8+ T cell function after the ﬁrst infection (Tsukamoto et al., 2007) or
due to polyfunctional virus-speciﬁc CD8+ T cells elicited by the
“immunizing virus” as reported in associated with attenuated
SHIV89.6 infection (Genesca et al., 2007). SIVrcm infection may also
act as a virulence-attenuated virus that induces relatively effective
immune responses against SIVmac251, but we did not sufﬁciently
examine cellular immune responses in this study.
In summary, this study provides information on CCR2-tropic
SIVrcm that could be valuable for studying infection of the mono-
cyte/macrophage lineage. The fact that SIVrcm is nonpathogenic after
7 serial passages shows that serial passage of SIV does not result in
increased virulence. Furthermore, SIVrcm infection suppresses sub-
sequent SIVmac251 replication, and it may have therapeutic or
vaccine-like effects via coreceptor interaction, immune protection or




Nine Indian-origin rhesus macaques (Ind Rh) were used for seven
serial passage of SIVrcm. One animal was used in each passage except
in the 7th passage which had 3 animals. Animals and passage are
described by animal number (e.g. AT74) followed by the passage
sequence (p1=ﬁrst passage) as AT74-p1, AT83-p2, AT87-p3, L836-p4,
R265-p5, P648-p5, M854-p6, CF56-p7, CG29-p7 and G454-p7. Three
macaques (AT87-p3, L836-p4, R265-p5) were subsequently intrave-
nously challenged 100 TCID50 SIVmac251 after the level of SIVrcm
load became undetectable. Another 8 naive Indian rhesus were
intravenously infected with 100 TCID50 SIVmac251 alone for
comparison with SIVrcm and SIVmac251 superinfected animals. All
animals were housed at the Tulane National Primate Research Center
(TNPRC) in accordance with the Guide for Care and Use of Laboratory
Animals and all animal protocols were approved by the TNPRC
Institutional Animal Care and Use Committee. Macaques were
conﬁrmed to be negative for SIV, simian D retrovirus and simian T-
cell leukemia virus infection prior to use. The ﬁrst animal (AT74-p1)
was inoculated with 1000 TCID50 of cell-free SIVrcm. Thereafter, the
2nd to 7th passage were conducted by collecting 5 ml of bone marrow
and 10 ml plasma at the peak viremia from the animal in each prior
passage. Bone marrow was used as a source of virus in order to
enhance potential pathogenicity of SIVrcm. All inoculations were
performed by intravenous route.
Blood and tissue sample collection and lymphocytes isolation
Blood, lymph node and intestinal tissue samples were collected
at various time points. EDTA-blood and plasma was used for viral
load quantiﬁcation. Peripheral blood mononuclear cells (PBMCs)
were isolated by lymphocyte separation medium and used for
further T cell subset immunophynotyping. Intestinal lymphocyteswere isolated as previously described (Ling et al., 2002; Veazey et al.,
1997, 1998). Brieﬂy, macaques were anesthetized and 10-15
duodenal or upper jejunal 1 mm diameter pinch biopsies were
collected using a ﬂexible endoscope. Lymphocytes were collected by
incubating biopsies in complete RPMI media containing 5 mM EDTA
followed by 2–3 digestions with 60 U/ml collagenase (type II, Sigma,
St. Louis, MO). To enrich lymphocytes, cells were layered on a
discontinuous 35%/60% Percoll gradients (Sigma, St. Louis, MO) and
centrifuged for 20 min at 1000 g, washed, and resuspended in RPMI
containing 5% FCS.
Cell culture for viral replication
PBMCswere separated from heparinized blood of a SIV naive rhesus
macaque using Lymphocyte Separation Medium (LSM). PBMCs were
stimulated with ConA (5 mg/ml) in complete cell culture medium
containing 10% fetal calf serum and antibiotics for 3 days, then washed.
PBMCs isolated from each infected animal were cocultured with the
same stimulated PBMCs from the SIV naive rhesus macaques for viral
production. The positive results were determined by the production of
SIV Gag p27 antigen in the culture supernatants by using SIV p27
Antigen ELISA Kit (ZeptoMetrix Co., Buffalo, NY) according to the
manufacturer's instructions.
Antibodies, immuoﬂuorescent staining and ﬂow cytometry
All antibodies (except anti-CCR2) were purchased from PharMin-
gen or BD biosciences (BD biosciences, San Jose, CA). For phenotypic
analysis, EDTA anticogulated whole blood and puriﬁed intestinal
lymphocytes were stained simultaneously with 4 different ﬂuores-
cently labeled antibodies in each tube including CD3-FITC, CD8-PerCP,
CD4-APC, CD45R-AFITC, CCR5-PE, CD3-PerCP, CCR2-PE (R and D
systems, Minneapolis, MN), CD20-PerCP and CD14-FITC. Samples
were ﬁxed overnight in 2% paraformaldehyde and analyzed on a FACS
Calibur Flow Cytometer. At least 50,000 events were acquired for each
sample. Data were analyzed using CellQuest Pro (BD Biosciences, San
Jose, CA) or FloJo software (Tree Star Inc., San Carlos, CA). Absolute
numbers of CD4+ and CD8+ T cells in peripheral blood were
determined using the true-count method as previously described
(Ling et al., 2002).
Quantiﬁcation of SIVrcm plasma loads by real-time PCR (RT-PCR)
Plasma viral load was measured by real-time PCR using a 7700 ABI
PRISM Sequence Detector (Applied Biosystems, Foster City, CA).
Brieﬂy, plasma viral RNA was used to generate cDNA using one-step
RT-PCR Master Mix (Applied Biosystems). Primers and probe
sequences were as follows: SIVrcm-F 5′ AGGGAAGAGAATCCAGATGT-
CATC-3′ (forward primer). SIVrcm-R 5′-GGGTCTCAAAGCCCCAGAAC-
3′(reverse primer). SIVrcm-P 6FAM-TTACCAGTACATGGATGATCT-
CTTTGTAGGCTCA-TAMRA (TaqMan probe). The following PCR condi-
tions were used: Reverse-transcription at 48 °C for 30 min,
denaturation at 95 °C for 10 min, followed by 40 cycles of heating at
95 °C for 15 s, annealing at 60 °C with a ﬁnal elongation of 7 min at
72 °C. Absolute precision in the quantiﬁcation of SIVrcm RNA in
samples containing unknown quantities of viral RNA was assured by
the parallel measurement of SIV RCM RNA standard. Standard
templates were created as follows: complementary DNA was am-
pliﬁed by PCR in a nested assay using outer primers OF (5′-
ATCTCCCGCCATCTTTC-3′), OR (5′-CCGCCATTAGTCCCATAC-3′) and
inner primers IF (5′-TCTCCCGCCATCTTTCA-3′) and IR (5′-GCAGCCTT-
CCCCAAATA-3′). The yielded PCR product was inserted in a TOPO-
TA Vector using TOPO TA cloning kit (Invitrogen, Carlsbad, CA) and
the recombinant plasmid was transformed into E. coli. The plasmid
was then extracted using Qiangen Plasmid Mini Kit (Qiagen) and
linearized by restriction enzymes. The linearized plasmid was then
43B. Ling et al. / Virology 379 (2008) 38–44used to perform an in vitro transcription (MEGAscriptTM High
Yield Transcription kit, Ambion). Viral copy numbers in each
sample were determined by plotting CT values against the
standard curve representing known viral copy numbers. The
efﬁciency of the RT-PCR reaction was N95%. The limit of detection
was 100 copies/ml.
Quantiﬁcation of SIVmac plasma loads by branched DNA assay
(bDNA assay)
Plasma viral loads of three animals that were challenged with
SIVmac were measured using the bDNA assay (Simens Diagnostics,
Berkeley, CA). This was because SIVmac251 and SIVrcm have a high
disparity in sequence and the SIVmac speciﬁc probes only detect
SIVmac group of strains including SIVmac239 and SIVmac251
(Greenier et al., 2001).
Statistical analysis
Nonparametric Mann–Whitney test was used for the percentage of
mucosal CD4+ T cells and memory CD4+CCR5+ T cells between each
time point. Values are expressed as median±interquartile range. All
reported p values were two-sided at the 0.05 signiﬁcance level using
Graph Pad Prism 4.0 software statistical program.
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